CY1115258T1 - Μεθοδοι και χρησεις που περιλαμβανουν τις γενετικες παρεκκλισεις του ναv3 και την παρεκκλινουσα εκφραση πολλαπλων γονιδιων - Google Patents

Μεθοδοι και χρησεις που περιλαμβανουν τις γενετικες παρεκκλισεις του ναv3 και την παρεκκλινουσα εκφραση πολλαπλων γονιδιων

Info

Publication number
CY1115258T1
CY1115258T1 CY20141100515T CY141100515T CY1115258T1 CY 1115258 T1 CY1115258 T1 CY 1115258T1 CY 20141100515 T CY20141100515 T CY 20141100515T CY 141100515 T CY141100515 T CY 141100515T CY 1115258 T1 CY1115258 T1 CY 1115258T1
Authority
CY
Cyprus
Prior art keywords
gene
nav3
relates
present
tumor
Prior art date
Application number
CY20141100515T
Other languages
English (en)
Inventor
Kai Krohn
Annamari Ranki
Emilia Carlsson
Kristian Ovaska
Valtteri Häyry
Sampsa Hautaniemi
Original Assignee
Valipharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valipharma filed Critical Valipharma
Publication of CY1115258T1 publication Critical patent/CY1115258T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Abstract

Η παρούσα εφεύρεση αφορά στα πεδία της γενετικής και της ογκολογίας και προβλέπει μεθόδους για την ανίχνευση όγκων, καθώς επίσης και μεθόδους για τη θεραπεία ασθενών και την πρόβλεψη της πρόγνωσης για έναν ασθενή. Συγκεκριμένα, η παρούσα εφεύρεση αφορά σε μέθοδο κατάδειξης του κακοήθους χαρακτήρα ενός όγκου ή υποπληθυσμού κυττάρων σε ένα άτομο και σε μέθοδο πρόβλεψης μιας πρόγνωσης, σε μια μέθοδο θεραπείας ενός ατόμου που έχει έναν όγκο με αλλαγή αριθμού αντιγράφων ΝΑV3 και με υπερέκφραση τουλάχιστον ενός γονιδίου ή γονιδιακού προϊόντος που επιλέγεται από συγκεκριμένους καταλόγους και σε μια μέθοδο επιλογής μιας θεραπείας για κάποιο άτομο. Η παρούσα εφεύρεση αφορά επίσης στις χρήσεις του γονιδίου ή του γονιδιακού προϊόντος ΝΑV3 και τουλάχιστον ενός γονιδίου ή/και γονιδιακού προϊόντος που επιλέγεται από συγκεκριμένους καταλόγους για την κατάδειξη του κακοήθους χαρακτήρα ενός όγκου ή υποπληθυσμού κυττάρων, για την πρόβλεψη μιας πρόγνωσης για ένα άτομο, για την επιλογή μιας θεραπείας για το άτομο και για τη θεραπεία του καρκίνου σε ένα άτομο που έχει έναν όγκο με αλλαγή αριθμού αντιγράφων ΝΑV3. Επιπλέον, η παρούσα εφεύρεση αναφέρεται επίσης σε μια χρήση ενός ανταγωνιστή, αντισώματος ή ανασταλτικού μορίου τουλάχιστον ενός γονιδίου ή/και γονιδιακού προϊόντος που επιλέγεται από συγκεκριμένους καταλόγους για τη θεραπεία καρκίνου σε ένα άτομο. Ακόμα, η παρούσα εφεύρεση αναφέρεται σε διαγνωστικό κιτ που περιλαμβάνει τα εργαλεία για την ανίχνευση της αλλαγής αριθμού αντιγράφων ΝΑV3 σε ένα βιολογικό δείγμα, καθώς και τα εργαλεία για την ανίχνευση της υπερέκφρασης τουλάχιστον ενός γονιδίου ή γονιδιακού προϊόντος που επιλέγεται από
CY20141100515T 2008-10-20 2014-07-09 Μεθοδοι και χρησεις που περιλαμβανουν τις γενετικες παρεκκλισεις του ναv3 και την παρεκκλινουσα εκφραση πολλαπλων γονιδιων CY1115258T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19676108P 2008-10-20 2008-10-20
EP09821644.3A EP2350316B1 (en) 2008-10-20 2009-10-19 Methods and uses involving genetic aberrations of nav3 and aberrant expression of multiple genes

Publications (1)

Publication Number Publication Date
CY1115258T1 true CY1115258T1 (el) 2017-01-04

Family

ID=42118980

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100515T CY1115258T1 (el) 2008-10-20 2014-07-09 Μεθοδοι και χρησεις που περιλαμβανουν τις γενετικες παρεκκλισεις του ναv3 και την παρεκκλινουσα εκφραση πολλαπλων γονιδιων

Country Status (12)

Country Link
US (2) US20120058108A1 (el)
EP (1) EP2350316B1 (el)
JP (1) JP5819728B2 (el)
AU (1) AU2009306260B2 (el)
CA (1) CA2740351A1 (el)
CY (1) CY1115258T1 (el)
DK (1) DK2350316T3 (el)
ES (1) ES2469802T3 (el)
PL (1) PL2350316T3 (el)
PT (1) PT2350316E (el)
SI (1) SI2350316T1 (el)
WO (1) WO2010046530A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX338883B (es) 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
AU2012301664A1 (en) * 2011-08-31 2014-02-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer
CN110890128B (zh) * 2018-09-10 2024-02-09 立森印迹诊断技术（无锡）有限公司 一种用于检测皮肤肿瘤良恶性程度的分级模型及其应用
WO2023157933A1 (ja) * 2022-02-18 2023-08-24 国立研究開発法人理化学研究所 細胞の系統解析を行う方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE19728737C1 (de) * 1997-07-04 1999-02-11 Johannes Christian Groeninghen Verfahren zur Erkennung und Bestimmung von GnRH-Rezeptoren und die Verwendung von GnRH-Agonisten und GnRH-Antagonisten zur Behandlung eines Tumors ausgehend vom Hirn und/oder Nervensystem und/oder den Hirnhäuten
US7834141B1 (en) * 2000-03-31 2010-11-16 Theresa Siler-Khodr Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy
DE10292896D2 (de) * 2001-07-05 2004-07-01 Univ Goettingen Georg August Gentherapeutisches Verfahren zur Behandlung von GnRH-Rezeptor-positiven Karzinomen durch GnRH induzierte tumorzellspezifische Aktivierung eines therapeutischen Gens, zugehörige Nukleinsäurekonstrukte und Vektoren
FI113666B (fi) * 2002-01-24 2004-05-31 Tapio Visakorpi Menetelmiä, joissa käytetään kromosomin 12 spesifisiä katkoskohtia ja/tai neuroninavigaattori 3 -geeniä ihon primaaristen T-solulymfoomien diagnosoimiseksi ja taudin etenemisen seuraamiseksi tai ennustamiseksi, sekä näiden katkoskohtien ja geenien käyttö
US20060281081A1 (en) * 2002-08-30 2006-12-14 Yusuke Nakamura Method of diagnosing colon and gastric cancers
BRPI0408247A (pt) * 2003-03-10 2006-03-01 Schering Corp usos de antagonistas e agonistas de il-23 e reagentes relacionados
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
SG142186A1 (en) * 2006-10-20 2008-05-28 Agency Science Tech & Res Breast tumour grading
EP2092081B9 (en) * 2006-11-13 2013-01-23 ValiPharma Methods and uses involving genetic abnormalities at chromosome 12

Also Published As

Publication number Publication date
EP2350316B1 (en) 2014-04-16
PL2350316T3 (pl) 2014-10-31
EP2350316A4 (en) 2012-05-30
JP5819728B2 (ja) 2015-11-24
JP2012505666A (ja) 2012-03-08
WO2010046530A8 (en) 2010-07-15
PT2350316E (pt) 2014-06-23
WO2010046530A1 (en) 2010-04-29
AU2009306260B2 (en) 2015-12-24
EP2350316A1 (en) 2011-08-03
SI2350316T1 (sl) 2014-09-30
US20160083798A1 (en) 2016-03-24
US20120058108A1 (en) 2012-03-08
DK2350316T3 (da) 2014-05-05
ES2469802T3 (es) 2014-06-20
AU2009306260A1 (en) 2010-04-29
CA2740351A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
Mishra MicroRNAs as promising biomarkers in cancer diagnostics
Babar et al. Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells
Gaedcke et al. Mutated KRAS results in overexpression of DUSP4, a MAP‐kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas
Gong et al. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis
Sun et al. Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine
Nagata et al. Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma
Yu et al. Epigenetic silencing of tumor suppressor gene CDKN1A by oncogenic long non-coding RNA SNHG1 in cholangiocarcinoma
Wu et al. Potentially predictive microRNAs of gastric cancer with metastasis to lymph node
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
Cipollini et al. MicroRNA binding site polymorphisms as biomarkers in cancer management and research
Lee et al. High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients
RU2015125575A (ru) Композиции и способы для лечения злокачественной опухоли
Li et al. Prognostic role of microRNA-21 expression in gliomas: a meta-analysis
Gruber et al. Evolving understanding of the CLL genome
EA201000334A1 (ru) Улучшенное определение экспрессии mage-a
Aref et al. Medulloblastoma: recurrence and metastasis
Sun et al. Screening of differently expressed miRNA and mRNA in prostate cancer by integrated analysis of transcription data
CY1115258T1 (el) Μεθοδοι και χρησεις που περιλαμβανουν τις γενετικες παρεκκλισεις του ναv3 και την παρεκκλινουσα εκφραση πολλαπλων γονιδιων
Gómez et al. A novel method for rapid molecular subgrouping of medulloblastoma
Gee et al. MicroRNA-related DNA repair/cell-cycle genes independently associated with relapse after radiation therapy for early breast cancer
Rosenblum et al. Predictive properties of DNA methylation patterns in primary tumor samples for osteosarcoma relapse status
WO2010102157A1 (en) Molecular predictors of biological response to a cenpe inhibitor in cancer
WO2006065940A3 (en) Identification and use of prognostic and predictive markers in cancer treatment
Gendoo et al. Personalized diagnosis of medulloblastoma subtypes across patients and model systems
Rice et al. Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in non-small cell lung cancer